{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-emetics", "query": { "intervention": "Anti-emetics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 164, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-emetics&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T11:19:48.511Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02959840", "title": "Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nausea", "Vomiting", "Satisfaction" ], "interventions": [ { "name": "Acupressure Point P6 stimulator", "type": "DEVICE" }, { "name": "Metoclopramide", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 180, "start_date": "2015-07", "completion_date": "2017-08-23", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959840" }, { "nct_id": "NCT06379217", "title": "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neuroendocrine Prostate Cancer" ], "interventions": [ { "name": "[68Ga]Ga-PSMA-11", "type": "DRUG" }, { "name": "[68Ga]GA-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-PSMA-617", "type": "DRUG" }, { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "L-Lysine HCl-L-Arginine HCl, 2.5 %,", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "GnRH antagonists", "type": "DRUG" }, { "name": "Antiemetics & antinauseants", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 31, "start_date": "2024-07-29", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06379217" }, { "nct_id": "NCT06637423", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-12-20", "completion_date": "2029-03-14", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 4, "location_summary": "Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06637423" }, { "nct_id": "NCT02456662", "title": "Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Drug-induced Nausea and Vomiting" ], "interventions": [ { "name": "Ondansetron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 319, "start_date": "2015-10-07", "completion_date": "2019-04-03", "has_results": true, "last_update_posted_date": "2020-04-16", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02456662" }, { "nct_id": "NCT05390736", "title": "Evaluating the Cost Effectiveness of STEADI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accidental Fall" ], "interventions": [ { "name": "Gait and balance assessment", "type": "BEHAVIORAL" }, { "name": "Medication review", "type": "BEHAVIORAL" }, { "name": "Comorbidity review", "type": "BEHAVIORAL" }, { "name": "Fall history", "type": "BEHAVIORAL" }, { "name": "Assessment of feet/footwear", "type": "BEHAVIORAL" }, { "name": "Assessment of visual acuity", "type": "BEHAVIORAL" }, { "name": "Home safety risk assessment", "type": "BEHAVIORAL" }, { "name": "Vitamin D Deficiency", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Opinion Research Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 780, "start_date": "2020-07-29", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05390736" }, { "nct_id": "NCT01770145", "title": "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease", "Motor Symptoms", "Akinesia", "Hypomobility", "Delayed Levodopa Onset" ], "interventions": [ { "name": "APOKYN", "type": "DRUG" }, { "name": "L-dopa", "type": "DRUG" }, { "name": "Trimethobenzamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2012-12", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 12, "location_summary": "Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Reseda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770145" }, { "nct_id": "NCT01054456", "title": "A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC" ], "interventions": [ { "name": "palonesetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2009-10-27", "completion_date": "2010-12-08", "has_results": true, "last_update_posted_date": "2020-12-23", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 9, "location_summary": "Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more", "locations": [ { "city": "Sunrise", "state": "Florida" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "Nyack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054456" }, { "nct_id": "NCT02277184", "title": "Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck" ], "interventions": [ { "name": "Ficlatuzumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity Modulated Radiotherapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Julie E. Bauman, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-09", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277184" }, { "nct_id": "NCT00548548", "title": "A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 774, "start_date": "2007-09", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 13, "location_summary": "Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548548" }, { "nct_id": "NCT00514540", "title": "Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 121, "start_date": "2006-05", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2020-09-01", "last_synced_at": "2026-09-02T11:19:48.511Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514540" } ] }